Raum Elke, Lietzau Susanne, Stegmaier Christa, Brenner H, Rothenbacher Dietrich
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Pharmacoepidemiol Drug Saf. 2008 May;17(5):485-94. doi: 10.1002/pds.1589.
To evaluate the management of cardiovascular risk factors in a population-based cohort of adults with diabetes mellitus in Germany.
For the 9953 participants (50-74 years of age) of the ESTHER study, diabetes mellitus, hypertension, dyslipidemia and the respective medication were documented at baseline by their primary care physician. Blood pressure was taken and lipid levels were determined from a blood sample drawn at recruitment. Lifestyle factors (smoking, BMI, physical activity) were documented by the participants. Prevalence of pharmacotherapy for and control of hypertension and dyslipidemia among diabetic patients with these diagnoses were assessed and determinants were evaluated by multiple logistic regression.
Diabetes mellitus was present in 1375 participants (14.2%). Almost 78% of diabetic participants had physician diagnosed hypertension, 86.0% received pharmacotherapy, but only 12.8% of those with anti-hypertensive medication achieved blood pressure levels below 130/85 mmHg. Obese participants were more likely to receive anti-hypertensive pharmacotherapy than non-obese ones: adjusted odds ratio (OR, 95% confidence interval (CI)): 3.58 (1.86-6.87). Gender had no influence on anti-hypertensive pharmacotherapy. Older diabetic patients with hypertension were less likely to have sufficient blood pressure control than younger ones. Dyslipidemia was documented in 50% of diabetic patients. Diabetic participants with coronary heart disease or hypertension were more likely to receive lipid-lowering pharmacotherapy than those without these conditions (adjusted OR 1.85 (95%CI 1.19-2.89) and 2.59 (95%CI 1.41-4.74), respectively).
For most elderly with diabetes cardiovascular risk factor management continues to be not in line with recommendations.
评估德国成年糖尿病患者人群中心血管危险因素的管理情况。
对于埃丝特研究的9953名参与者(年龄在50 - 74岁之间),其初级保健医生在基线时记录了糖尿病、高血压、血脂异常及相应药物治疗情况。在招募时测量血压并从采集的血样中测定血脂水平。参与者记录生活方式因素(吸烟、体重指数、身体活动)。评估糖尿病患者中高血压和血脂异常的药物治疗患病率及控制情况,并通过多因素逻辑回归评估决定因素。
1375名参与者(14.2%)患有糖尿病。近78%的糖尿病参与者被医生诊断为高血压,86.0%接受了药物治疗,但使用抗高血压药物的患者中只有12.8%的血压水平低于130/85 mmHg。肥胖参与者比非肥胖参与者更有可能接受抗高血压药物治疗:调整后的优势比(OR,95%置信区间(CI)):3.58(1.86 - 6.87)。性别对抗高血压药物治疗无影响。老年糖尿病合并高血压患者比年轻患者更难实现血压充分控制。50%的糖尿病患者有血脂异常记录。患有冠心病或高血压的糖尿病参与者比没有这些疾病的参与者更有可能接受降脂药物治疗(调整后的OR分别为1.85(95%CI 1.19 - 2.89)和2.59(95%CI 1.41 - 4.74))。
对于大多数老年糖尿病患者,心血管危险因素管理仍不符合推荐标准。